Paper: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial
Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid Malignancies 1 Medica l College of Wisconsin, Milwaukee, WI 2 Dana-Farber Cancer Institute / ECOG-ACRIN Biostatistics, Bostin, MA 3 Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 4 Emory University / Winship Cancer Institute, Atlanta, GA 5 University of
